X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Recognizing National Sickle Cell Awareness Month

By Anne McDonald Pritchett, PhD  |    September 23, 2022
September is National Sickle Cell Awareness Month and a time for us to underscore the biopharmaceutical industry’s ongoing commitment to improve the lives of patients, families and communities...   Read More

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

By Andrew Powaleny  |    August 16, 2022
Innovative biopharmaceutical research companies have been dedicated to fighting COVID-19 for over two years. Since the start of the pandemic, America’s biopharmaceutical companies have worked around...   Read More

This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy

By Nicole Longo  |    August 10, 2022
Last weekend, the Senate passed the Inflation Reduction Act which includes dangerous price-setting provisions. The bill now heads to the House for consideration, where it is not too late for them to...   Read More

Myth vs. Fact: The Senate’s latest price setting proposal

By Nicole Longo  |    August 5, 2022
The narratives being built around the Senate’s latest price setting proposal frame it as a bill intended to lower drug prices for patients and address rising inflation. But those narratives aren’t...   Read More

An open letter to Congress: Stand with patients and future cures

By Stephen J. Ubl  |    August 4, 2022
I recently joined PhRMA board members in penning the letter below to Congress, urging them to abandon their latest drug pricing proposal. You can read the letter here or below:   Read More

The Senate’s latest price setting proposal will undermine U.S. economic growth

By Nicole Longo  |    August 3, 2022
Last week, we examined ways the latest drug pricing proposal will undermine patient access to medicines, American medical innovation and our health care system as a whole. But there is another...   Read More

New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers

By Brian Newell  |    August 1, 2022
A new analysis by the health care analytics and research firm Avalere reveals the partisan drug pricing bill will have a much deeper impact on the biopharmaceutical research industry than previously...   Read More

ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill

By Brian Newell  |    July 29, 2022
During a widely attended media briefing, physicians, biopharmaceutical leaders, and a brave cancer survivor, all expressed their strong opposition to the extreme drug pricing bill Congress is...   Read More

The Senate’s latest price setting proposal will undermine: American medical innovation

By Nicole Longo  |    July 27, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021

By Tim McClung  |    July 18, 2022
PhRMA member companies’ continued investment in research and development (R&D) has led to new medicines transforming human health. Innovative biopharmaceutical approaches to treating patients for a...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates